Grant: Discovery Grants Program - Individual
University of Ottawa
$23,000.00
Dissecting in vitro models for toxicology
EF 2011-12
Résumé
The use of tissue engineered tissues and organs as in vitro alternatives to animal testing is gaining importance, especially in the context of the ban on animal testing for consumer products currently in place in Europe (EU Directive 76/768/EEC) which is expected to expand worldwide. To standardize in vitro models for testing, care must be taken to assure that each ""alternative"" not only mimics the tissue architecture as the target, but also shares key biochemical, morphological, physiological, and even genetic components. Tissue engineering methods utilize a wide range of synthetic polymers to natural biomaterials (with or without additional bioactive co-factors) as scaffolding to create appropriate 3-dimensional environments upon which cells can attach to proliferate and differentiate into physiologically functional tissues that are structurally similar to the native tissue. The understanding of how ""tissue forms and architecture"" (scaffolds) regulates tissue development and function, however, is somewhat lacking, making comparison amongst models daunting, as different groups will report different safety and efficacy results based on the model they have selected. Our objective is to dissect out the developmental mechanisms involved in engineering tissues, specifically the role of biomaterials as scaffolding used in reconstructing whole tissues. We focus on the cornea as a test bed since ocular irritancy testing is widely used in industry for safety testing of compounds for personal use and household consumer products. Very briefly, to keep things manageable, we focus only the biomaterials that are commonly used as scaffolding in in vitro corneal tissue engineering to answer the following questions: What is the best type of material for scaffolds - an inert, degradable synthetic polyester, an inert plant-based fibre or biointeractive protein? Or, does the scaffold matter at all, or it is all in optimization of the mechanical properties or topology of the scaffolding? Once we have identified the fundamental desired characteristics of the basic scaffold, we will use this knowledge to develop 1) an in vitro disease model for drug efficacy testing; and 2) a fully synthetic analog of a corneal model for safety/ toxicology testing.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
227951-2010
Name nom
Griffith, May
Department département
Cellular and Molecular Medicine
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2010
Award amount
23000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
2
Nb partie
5
Application title
Dissecting in vitro models for toxicology
Keyword
NSERC
Application summary
The use of tissue engineered tissues and organs as in vitro alternatives to animal testing is gaining importance, especially in the context of the ban on animal testing for consumer products currently in place in Europe (EU Directive 76/768/EEC) which is expected to expand worldwide. To standardize in vitro models for testing, care must be taken to assure that each ""alternative"" not only mimics the tissue architecture as the target, but also shares key biochemical, morphological, physiological, and even genetic components. Tissue engineering methods utilize a wide range of synthetic polymers to natural biomaterials (with or without additional bioactive co-factors) as scaffolding to create appropriate 3-dimensional environments upon which cells can attach to proliferate and differentiate into physiologically functional tissues that are structurally similar to the native tissue. The understanding of how ""tissue forms and architecture"" (scaffolds) regulates tissue development and function, however, is somewhat lacking, making comparison amongst models daunting, as different groups will report different safety and efficacy results based on the model they have selected. Our objective is to dissect out the developmental mechanisms involved in engineering tissues, specifically the role of biomaterials as scaffolding used in reconstructing whole tissues. We focus on the cornea as a test bed since ocular irritancy testing is widely used in industry for safety testing of compounds for personal use and household consumer products. Very briefly, to keep things manageable, we focus only the biomaterials that are commonly used as scaffolding in in vitro corneal tissue engineering to answer the following questions: What is the best type of material for scaffolds - an inert, degradable synthetic polyester, an inert plant-based fibre or biointeractive protein? Or, does the scaffold matter at all, or it is all in optimization of the mechanical properties or topology of the scaffolding? Once we have identified the fundamental desired characteristics of the basic scaffold, we will use this knowledge to develop 1) an in vitro disease model for drug efficacy testing; and 2) a fully synthetic analog of a corneal model for safety/ toxicology testing.